White Paper:

Spinal Muscular Atrophy: Outlook and Implications for Biopharma (Part 2)

Spinal Muscular Atrophy (SMA) is a devastating disease, but recent therapeutic advances are delivering major benefits for patients. In Part 1, we reviewed the disease biology and therapeutic approaches currently marketed to treat SMA. Here, we look to the future and discuss ongoing and potential advancements that will impact the therapeutic and commercial landscape.

  • Hidden
  • This field is for validation purposes and should be left unchanged.